CADTH Canadian drug expert committee recommendation: Ustekinumab (Stelara/Stelara I.V. -- Janssen Inc.) : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis
Ustekinumab is a human monoclonal antibody that affects the interleukin pathways in the pathogenesis of inflammatory bowel disease (IBD) and other immunomodulated conditions. It is approved by Health Canada for the treatment of adults with chronic moderate-to-severe plaque psoriasis, active psoriati...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Ustekinumab is a human monoclonal antibody that affects the interleukin pathways in the pathogenesis of inflammatory bowel disease (IBD) and other immunomodulated conditions. It is approved by Health Canada for the treatment of adults with chronic moderate-to-severe plaque psoriasis, active psoriatic arthritis, and Crohn disease. The current indication under review is for thetreatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, orwere intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. The recommended dosage for ustekinumab in the treatment of UC is as a single weight-based IV infusion (approximating 6 mg/kg) followed by a 90 mg SC dose eight weeks later, then 90 mg SC every eight weeks thereafter. T |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (9 pages) |